Publications | PubMed=8459226; DOI=10.1084/jem.177.4.989; PMCID=PMC2190978 Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., Herlyn M., Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177:989-998(1993) PubMed=7520026; DOI=10.1002/ijc.2910580413 Hersey P., Si Z.-Y., Smith M.J., Thomas W.D. Expression of the co-stimulatory molecule B7 on melanoma cells. Int. J. Cancer 58:527-532(1994) PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-# Thomas W.D., Smith M.J., Si Z.-Y., Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer 68:795-801(1996) PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195 Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195-2200(1998) DOI=10.1007/0-306-46872-7_16 Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G. Melanoma: the Milan melanoma cell lines. (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999) PubMed=10338330; DOI=10.1097/00008390-199902000-00003 Rizos H., Darmanian A.P., Indsto J.O., Shannon J.A., Kefford R.F., Mann G.J. Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res. 9:10-19(1999) PubMed=15048078; DOI=10.1038/sj.onc.1207563 Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P.S., Ringner M., Hayward N.K. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23:4060-4067(2004) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676 Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11:888-897(2012) PubMed=22553342; DOI=10.1158/1078-0432.CCR-11-2232; PMCID=PMC3426233 Tassi E., Zanon M., Vegetti C., Molla A., Bersani I., Perotti V., Pennati M., Zaffaroni N., Milella M., Ferrone S., Carlo-Stella C., Gianni A.M., Mortarini R., Anichini A. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin. Cancer Res. 18:3316-3327(2012) DOI=10.13130/grazia-giulia_phd2016-02-18 Grazia G. Co-targeting of oncogenic and death receptors pathways in human melanoma: pre-clinical rationale for a pro-apoptotic and anti-angiogenic strategy. Thesis PhD (2015); Universita degli studi di Milano; Milano; Italy |